Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Fishelson
Maayan Fishelson, Ramat Hasharon IL
| Patent application number | Description | Published |
|---|---|---|
| 20100058259 | OPTIMIZATION OF VERIFICATION OF CHIP DESIGN - Embodiments of methods and apparatus for optimization of verification of a chip design are disclosed. In various embodiments, a method for reducing a number of points to be verified during a verification process is disclosed, the method comprising selecting a first and a second verification point of a model of an integrated circuit design, determining whether the first and second verification points are isomorphic, and outputting the result of the determining to enable the first and second verification points being verified by verifying only a selected one of the first and second verification points in case the first and the second verification points are isomorphic. Additional variants and embodiments may also be disclosed and claimed. | 03-04-2010 |
Nikolay Fishelson, Lod IL
| Patent application number | Description | Published |
|---|---|---|
| 20100133107 | METHOD FOR ELECTROCHEMICAL DEPOSITION OF MONOLAYERS ON METALLIC SURFACES AND OBJECTS COATED WITH AN ORGANIC MONOLAYER - The present invention generally provides methods for the electrodeposition of organic monolayers onto the surfaces of a great variety of objects. | 06-03-2010 |
Zvi Fishelson, Tel-Aviv IL
| Patent application number | Description | Published |
|---|---|---|
| 20100278841 | DOWN-REGULATION OF MORTALIN BY siRNA - Use of a siRNA molecule selected from the group consisting of SEQ ID NO: 173 to 344 for treating a disease associated with a pathological cell population in a subject in need thereof is disclosed. Pharmaceutical compositions and articles of manufacture comprising the siRNAs are also disclosed. | 11-04-2010 |
| 20110059070 | Combination therapy for tumoral desease treatment - The invention provides a method of treating cancer by administering to a subject in need thereof, the subject being treated with an anti-cancer antibody therapy, a therapeutically effective amount of a delocalized lipophilic cation (DLC) compound such as MKT-077 which is capable of binding mortalin as an adjuvant for the anti-cancer antibody therapy. Also provided are pharmaceutical compositions and article of manufacturer for treating cancer which comprise the DLC compound as an adjuvant for anti-cancer antibody therapy. | 03-10-2011 |